ArticlemedRxiv : the preprint server for health sciences2025

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma.

Lilit Karapetyan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.